Diallyl trisulfide reverses drug resistance and lowers the ratio of CD133+ cells in conjunction with methotrexate in a human osteosarcoma drug-resistant cell subline
Diallyl trisulfide reverses drug resistance and lowers the ratio of CD133+ cells in conjunction with methotrexate in a human osteosarcoma drug-resistant cell subline
复制标题
二烯丙基三硫醚与甲氨蝶呤联用逆转人骨肉瘤耐药细胞亚系耐药性并降低CD133+细胞比例
DOI：
10.3892/mmr_00000091
复制
发表时间：
2009-03-01
影响因子：
3.4
通讯作者：
Li, Jianmin
中科院分区：
文献类型：
--
作者：
Li, Ji;Liu, Wei;Li, Jianmin
P-糖蛋白（P-gp）的过度表达和肿瘤干细胞被认为是肿瘤细胞交叉耐药的重要因素。二烯丙基三硫（DATS）能否逆转人骨肉瘤细胞的耐药性尚未见报道。在本研究中，我们证明，DATS下调P-gp表达和逆转耐药性。DATS和甲氨蝶呤（MTX）降低了CD 133（肿瘤干细胞标志物）阳性的耐药人骨肉瘤细胞的比例。据我们所知，这是第一个证据表明，DATS可以逆转耐药性和降低CD 133（+）细胞在人骨肉瘤细胞中的比例与MTX。
P-glycoprotein (P-gp) overexpression and tumor stem cells are thought to be important factors in the cross-resistance of cancer cells. There have been no studies on whether diallyl trisulfide (DATS) can reverse drug resistance in human osteosarcoma cells. In the present study, we demonstrated that DATS down-regulated P-gp expression and reversed drug resistance. DATS and methotrexate (MTX) decreased the ratio of drug-resistant human osteosarcoma cells positive for CD133 (a tumor stem cell marker). To the best of our knowledge, this is the first evidence that DATS can reverse drug resistance and lower the ratio of CD133(+) cells in human osteosarcoma cells in conjunction with MTX.